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Key Points
• TP53 39UTR variations
demonstrate prognostic value
in DLBCL.
We identifiedmultiple single nucleotide variants (SNVs) in the TP53 39 untranslated region
(39UTR) in tumor specimens from 244 patients with diffuse large B-cell lymphoma
(DLBCL). Patients carrying a wild-type TP53 coding sequence (CDS) and 1 or more 39UTR
SNVs had a better 5-year survival rate than patients carrying a wild-type CDS and the
reference 39UTR, yet there is no statistically significance difference in overall survival
(OS). In contrast, 39UTR variation predicted poorer OS for patients with a mutant TP53
CDS.We then sequenced TP53 39UTR in 247 additional DLBCL patients as a validation set. Altogether, we identified 187 novel SNVs; 36
occurred at least twice. Most of the newly identified 39UTR SNVs were located at sites that are complementary to seed sequences of
microRNAs (miRNAs) that are predicted or experimentally known to targetTP53. ThreeSNVsdisrupt the seedmatch betweenmiR-125b
and the TP53 39UTR, thereby impeding suppression of p53 by thismiRNA. In addition, a germline SNV (rs78378222) located in the TP53
polyadenylation signal resulted in downregulation of both p53 messenger RNA and protein levels and reduction of cellular apoptosis.
This study is the first to demonstrate the prognostic value of the TP53 39UTR in cancer. (Blood. 2013;121(22):4529-4540)
Introduction
The tumor suppressor p53, encoded by TP53, is recognized as the
guardian of the human genome. p53 responds to diverse stressors by
regulating many downstream target genes that promote cellular DNA
repair, apoptosis, cell cycle arrest, and senescence. Restoring p53
function alone is sufﬁcient to cause regression of several types of
cancer in mice.1,2 This characteristic suggests that p53 itself or the
p53 pathway must be derailed for tumor development, genetically or
otherwise. Three distinct sets of nucleotide alterations can occur in the
human TP53 gene: tumor-associated (somatic) mutations, germline
Li-Fraumeni mutations, and germline p53 polymorphisms.3,4 Both
tumor-associated mutations and Li-Fraumeni mutations occur in the
p53 coding sequence (CDS) and produce mutant p53 proteins that
lack most or all of the normal p53 functions and confer oncogenic
properties.5 For instance, a missense base substitution at codon 273 of
human TP53 (R273H) is frequently observed in somatic tumors and
in tumors from Li-Fraumeni syndrome patients. Mouse models
demonstrate that this mutant p53 allele has enhanced oncogenic
potential that cannot be explained by simple loss of p53 function.6,7
In general, p53 CDS mutations contribute to oncogenesis by 2
distinct mechanisms: (1) mutant alleles can have dominant negative
effects on wild-type (WT) p53 function; and (2) mutant p53 protein
can actively promote tumorigenesis independently of WT p53
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function. It is accepted that the WT TP53 CDS produces native p53
tumor suppressor, whereas most TP53 CDS mutations produce
oncogenic mutant p53. By contrast, only a few of the.200 naturally
occurring germline variants of TP53 in human populations cause
measurable perturbation of p53 function.3 More than 90% of these
p53 variants occur in 10 introns alleged to have no cancer-related
biological consequences. None of the 20 variants in the TP53
CDS have been linked reproducibly to cancer predisposition.3,4 The
best-studied TP53 CDS polymorphism is codon 72 (R72P), owing to
an earlier ﬁnding that human papillomavirus causes more efﬁcient
degradation of p53R72 than p53P72.8 However, few associations
between this polymorphism and various types of cancer have been
found.3 Sequence variation in the untranslated regions (UTRs) of the
TP53 gene has not been extensively studied.
Diffuse large B-cell lymphoma (DLBCL) is the most common
type of lymphoma and is clinically heterogeneous with subsets of
patients with better or worse prognosis.9,10 Biologically, DLBCL has
been known to be heterogeneous with germinal center B-cell (GCB)
and activated B-cell (ABC) subtypes. Recent advancements in next-
generation sequencing have further broadened our understanding of
genetic lesions in DLBCL. Three DLBCL-sequencing projects have
provided a wealth of information on whole genomes, exomes, and/or
transcriptomes for more than 100 DLBCL patient specimens, some
with matched healthy tissues as controls.11-13 These studies have
identiﬁed mutations inmore than 100 genes not implicated previously
in DLBCL pathogenesis, including genes involved in chromatin
modiﬁcation and immune regulation. The TP53 gene (the CDS) was
found to be mutated in ;20% of DLBCL cases in all 3 deep-
sequencing projects. However,MLL2,11,13 CREBBP,11 EZH2,12
BCL2,12 GNA13,13 BTG1,13 PIM1,13 and PCLO13 were found to
be mutated more frequently than the TP53 CDS in some of these
studies. These ﬁndings challenge the notion that TP53 is the most
commonly mutated gene in cancer14,15 at least within the context of
DLBCL. In addition, noncoding genomic sequences have been
largely overlooked in these sequencing projects.11,12
In a previous study, we found that ;20% of DLBCL patients who
received cyclophosphamide, doxorubicin, vincristine, and prednisone
(CHOP) chemotherapy had TP53 CDS mutations and that these
mutations adversely affected prognosis.16 To provide an in-depth
analysis of DLBCL patients treated with CHOP plus the monoclonal
antibody rituximab (R-CHOP), we assembled a multicenter study
designated as the DLBCL R-CHOP Collaborative Consortium. We
reported that TP53 CDS mutations predicted poorer survival in 506
(largest-ever cohort) R-CHOP–treated DLBCL patients with either the
GCBor theABCsubtype, and thatTP53monoallelic deletionand lossof
heterozygositydidnot conferworse survival.17Theseﬁndings suggested
that assessmentofTP53CDSmutation status canbeuseful for stratifying
patients receiving R-CHOP treatment into distinct prognostic subsets.
In this study, we retrospectively sequenced the TP53 59UTR and
39UTR in DLBCL patients to determine if TP53 39UTR sequence al-
terations occur in cancer patients and to assess their potential prognostic
importance. We also evaluated the potential impact of TP53 39UTR
sequence variation in combination with CDS mutations, and we deter-
mined the functional signiﬁcance of 39 UTR variants in p53 regulation.
Materials and methods
Patients
For the initial study group, we randomly selected 244 patients (training set) with
DLBCL from a total of 506 de novo DLBCL patients treated with R-CHOP,
whose TP53CDSs had been sequenced in a previous study by our consortium.17
For the validation set, tumor specimens were also obtained from 247 DLBCL
patients receiving R-CHOP treatment in the consortium program, none of whom
were included in the 506 DLBCL patients in the previous p53 CDS study.17
All cases were reviewed by a group of hematopathologists (S.M.M.,
M.A.P., M.B.M., A.T., and K.H.Y.), and the diagnoses conﬁrmed by World
Health Organization classiﬁcation criteria. The current study and material
transfer agreement were approved by the institutional review board of each
participating center. The overall collaboration was approved by the Insti-
tutional Review Board of The University of Texas MD Anderson Cancer
Center, Houston, Texas. This study was conducted in accordance with the
Declaration of Helsinki.
All of these patients have undergone molecular and phenotypic
classiﬁcation with available clinical data. There are no statistical differences
in regard to clinical parameters (age, gender, stage, lactic dehydrogenase
level, tumor size, performance status, chemotherapy regimen, survival time,
and recurrence rate), GCB/ABC classiﬁcation and distribution, and survival
among 3 groups (244 cases in the training set, 247 cases in the validation
set, and unselected remaining 262 cases).
DNA sequencing and cell biology
Genomic DNA was extracted from formalin-ﬁxed, parafﬁn-embedded
tissue samples using the HighPure parafﬁn DNA extraction kit (Qiagen).
The TP53 UTRs were sequenced bidirectionally using the Sanger method
at Polymorphic DNA Inc. (Alameda, CA). All sequences were compared
with the TP53 reference sequence (NM_000546.5). Single nucleotide
variants (SNVs) in the 39UTR were grouped into single nucleotide
polymorphisms (SNPs) and novel SNVs (nSNVs). Any nucleotide change
listed in the dbSNP database was considered an SNP; the remainder (none
occurring in >1% of patients) were considered nSNVs.
The p53-null human lung adenocarcinoma cancer cell line H1299
was obtained from the American Type Culture Collection (Manassas,
VA). For mutational analysis, the p53 expression vector pCMV-p53
(Clontech, Mountain View, CA) was modiﬁed to contain TP53 59 and
39UTRs as well as the 2.5-kb genomic DNA downstream of the 39UTR.
The resulting constructs were designated as TP53Ext, TP53ExtC1170T,
and TP53ExtA1175C, respectively. MicroRNA (miRNA) expression
vectors and Western blotting analysis were described previously18 and
are included in the supplemental Materials and methods (see the Blood
Web site).
Statistical analysis
All statistical calculations were performed using GraphPad Prism 5. Overall
survival (OS) was calculated from time of diagnosis to time of death from any
cause or last follow-up. Progression-free survival (PFS) was calculated from
time of diagnosis to time of progression or death from any cause. The actuarial
probabilities of OS and PFS17 were determined using the Kaplan-Meier
method, and differences were compared using the log-rank test. The 5-year
survival and 5-year PFS rates describe the percentage of patients that are alive
5 years after their cancer is diagnosed; they were compared using Fisher’s
exact test. All differences with P < .05 were considered statistically
signiﬁcant.
Results
Distribution and frequency of SNVs in TP53 UTRs in 244 de
novo DLBCL patients
In the initial group of 244 DLBCL samples, we identiﬁed 128 SNVs
in the UTRs of 107 patients, with 14 in the 59UTR and 114 in the
39UTR (Figure 1A; supplemental Table 1). Six 39UTR SNVs have
been reported as SNPs in dbSNP and occurred 37 times (Table 1).We
designated the newly found noncoding SNVs in the TP53 gene as
nSNVs. A total of 108 nSNVs were identiﬁed with 121 occurrences
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in the 39UTR in 76 patients. More patients had at least 1 nSNV in the
39UTR (n 5 76, 31%) than they had nonsynonymous mutations in
the CDS (n 5 49, 20%). In the 76 patients with 39UTR nSNVs, 32
(42%) had multiple lesions, compared with 2 of 49 (4%) patients with
2 or more CDS mutations. Ten of the TP53 39UTR nSNVs occurred
twice, and 1 occurred 3 times (Figure 1A). The 59UTR SNVs
occurred at a much lower frequency (n 5 15 patients, 6%; sup-
plemental Table 1; none of them reported in dbSNP) and were not
further analyzed in the current study.
Most TP53 CDS somatic mutations are clustered within exons 5
to 8.19 Although the nucleotide length (544 bp) of exons 5 to 8
accounts for only ;46% of the coding exons (1182 bp), mutations
in these exons account for 94% of all CDS somatic mutations.19
Our analysis of TP53 CDS in the 506 DLBCL patients conﬁrmed
the uneven codon distribution of single nucleotide missense sub-
stitutions: mutations in exons 5 to 8 account for 90% of all mu-
tations in coding exons (exons 3-10 plus parts of exon 2 and exon
11).17 In the initial study group of 244 patients, 92% of all CDS
mutations were found in exons 5 to 8 (45 of 49 cases, Figure 1B).
In contrast, 39UTR nSNVs were evenly dispersed across the
1207-bp 39UTR in the 76 patients with nSNVs (Figure 1A). The
distribution of SNVs in the 59UTR in the 244 cases was similar to
that in the 39UTR (Figure 1C). These data suggest that UTR
variants in the TP53 gene are distributed more evenly than are
CDS mutations.
Survival in relation to clinical characteristics and TP53
39UTR variation
The clinical and biological characteristics of the 244 DLBCL patients
and their impact on OS and PFS are summarized in supplemental
Table 2. We ﬁrst veriﬁed that no adverse clinical variables were
associated with variation in the 39UTR. When patients were divided
based on the presence of TP53 39UTR lesions (SNPs only, nSNVs
only, or any SNVs [either SNP or nSNV]), no signiﬁcant difference in
OS or PFS was found (Figure 2). TP53 CDS mutations (MUT-CDS)
predicted poorer OS (P 5 .0028) and PFS (P 5 .0086) in this 244-
patient cohort (Figure 3A-B). We then divided patients into 2 groups
according to the p53 CDS status and analyzed survival in relation to
SNVs. We found that SNPs in the TP53 39UTR had no impact on
Figure 1. Distribution of variation in the TP53 gene in 244 de novo DLBCL patients. (A) Distribution of SNVs in the 39UTR (part of exon 11; nucleotides 1385-2591 of
NM_000546.5 of the TP53 reference mRNA). (B) Distribution of CDS mutations in exons 3 to 10 and part of exons 2 and 11 (top bar; nucleotides 203-1384 of NM_000546.5).
(C) Distribution of 59UTR SNVs in exon 1 and part of exon 2, nucleotides 1-202 of NM_000546.5. Numbers on the top indicate exons.
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patient OS or PFS (supplemental Figure 1). Of the patients with WT-
CDS only, those without nSNVs (n 5 136) seemed to have poorer
OS and PFS than those with nSNVs (n5 59), but the difference was
not statistically signiﬁcant (P 5 .15 for OS; P 5 .17 for PFS,
respectively; Figure 3C-D). When 5-year survival rates were
calculated, nSNVs conferred better survival in patients with WT-
CDS (78% vs 59%, P5 .025), and 5-year PFS also showed a trend
(76% vs 58%, P 5 .079). In contrast, patients with MUT-CDS and
nSNVs (n 5 17) had poorer OS and PFS than did patients with
MUT-CDS and no nSNVs (n 5 32; P5 .019 for OS; P5 .018 for
PFS; Figure 3E-F). Indeed, all patients with MUT-CDS and nSNVs
died within 76 months after diagnosis (Figure 3E). We also
combined SNPs and nSNVs as total SNVs; there were similar
survival trends, but they were not statistically signiﬁcant (supple-
mental Figure 2). After the cohort was divided into ABC- and GCB-
DLBCL subsets, the prognostic impact of nSNVs in OS seemed to
favor patients with WT-CDS and not favor patients with MUT-CDS
in the GCB subset. Yet none were statistically signiﬁcantly, most
likely due to a smaller cohort (supplemental Figure 3). Again,
nSNVs conferred better 5-year survival in GCB patients with WT-
CDS (P 5 .0006). We did not ﬁnd statistical differences in
frequencies of subtypes, CDS mutation, and TP53 monoallelic
deletion between patients with nSNVs and those without.
Validation of TP53 39UTR variants
To determine whether nSNVs are common in DLBCL, we sequenced
the TP53 39UTR in tumor samples from an additional 247 DLBCL
patients. We found 106 nSNVs in 70 (28%) patients with 5 occurring
twice. All 6 SNPs identiﬁed in the initial set were found in this 247
patient group (Table 1; supplemental Table 3). For the combined 491
patients, 187 nSNVs were identiﬁed in the TP53 39UTR: 151
occurred once, 31 occurred twice, and 5 occurred 3 times (sup-
plemental Table 4). These data indicate that nSNVs in the TP53
39UTR occur frequently in DLBCL. In addition, nSNVs were dis-
persed across the whole TP53 39UTR (Figure 4A), providing
additional evidence that 39UTR nSNVs are distributed more evenly
than are CDS mutations.
39UTR variants in miRNA-binding sites
ElevenmiRNAs are reported to target the human TP53 gene: miR-25,
miR-30d,20 miR-125b,21 miR-504,22 miR-380-5p,23 miR-92a, miR-
141,24 miR-200a,25 miR-1285,26 miR-15a, and miR-16.27 Among
these miRNAs, 3 pairs have the same seed sequence: miR-25 andmiR-
92a, miR-141 and miR-200a, and miR-15a and miR-16. In addition,
miR-504 andmiR-1285 target 2 sites each. Therefore, the TP53 39UTR
has a total of 10 experimentally validated miRNA-targeting sites.
Table 1. Frequency of known TP53 39UTR SNPs in DLBCL cohorts
SNP ID Position† MAF‡ Heterozygous frequency Validation§
SNP occurrence*
First group (244) Second group (247)
rs8065799 9 A.C N/A N/A — 0 0
rs1042526 37 A.T N/A N/A Precious 0 0
rs35919705 105 C.T 0.010 0.015 Frequency 0 0
rs16956880 205 G.A 0.032 0.024 Cluster, Frequency, 1000Genome 3 2
rs79516338 309 G.A N/A 0.500 Frequency 0 0
rs34486624 314 G.A N/A 0.020 Frequency 0 0
rs17881366 328 G.A 0.026 0.010 Cluster, Frequency, 1000Genome 0 0
rs4968187 485 G.A 0.035 N/A Cluster, Frequency, 1000Genome Precious 11 5
rs916131 491 G.A N/A N/A Precious 0 0
rs916132 514 T.C N/A N/A Precious 0 0
rs1811095 534 C.T N/A N/A Cluster 0 0
rs35944977 534-535 TC.CT N/A N/A — 0 0
rs1811096 535 C.T N/A N/A — 0 1
rs17886358 569-570 GT.del N/A 0.435 Cluster, Frequency 0 0
rs34607064 595 C.del N/A N/A — 0 0
rs66759322 611 A.del N/A N/A — 0 0
rs17879353 613 C.A 0.007 N/A Cluster, Frequency 1 1
rs1042535 634 C.CG.G.GA N/A N/A — 0 0
rs1794291 635 A.G N/A N/A Cluster 0 0
rs34182553 674 C.del N/A N/A — 0 0
rs77011241 773 C.T N/A 0.389 Frequency, 1000Genome 0 0
rs35940853 798 T.del N/A N/A — 0 0
rs17884306 826 G.A 0.044 N/A Cluster, Frequency, 1000Genome, Precious 17 24
rs17884586 855 C.T N/A 0.012 — 0 0
rs35659787 886 G.A N/A 0.10 Frequency 0 0
rs55817367 925 C.T 0.007 N/A 1000Genome 0 0
rs1794292 995 G.C N/A N/A — 0 0
rs1794293 1057 C.G N/A N/A — 0 0
rs114831472 1070 C.T 0.032 0.065 1000Genome 2 1
rs78378222 1175 A.C 0.010 N/A Cluster, Frequency, 1000Genome 3 4
*Minor allele found in the initiation set (244 cases) or the validation set (247 cases). Some patients possess more than 1 SNP. Underlining in column 2 indicates SNPs
found in the cohort.
†Counted from first nucleotide of the TP53 39UTR; “del,” deletion.
‡MAF, minor allele frequency; N/A, not available.
§Validation: “Cluster,” multiple submissions mapped to the same location and clustered into 1 refSNP cluster and assigned a reference SNP ID number; “Frequency,”
validated by both population frequency data and genotype data; “1000Genome,” validated by the 1000 Genomes Project; “Precious,” cited as clinically relevant in the literature
and belonging to a reserved set of clinically associated SNPs in dbSNP.
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Except for the miR-141 and miR-380-5p sites, 8 of 10 miRNA
sites had 1 or more nSNVs occurring at least once in 491 patients
(Table 2). We analyzed the potential of nSNVs to affect putative
miRNA binding as predicted by TargetScan,28,29 in which 8
nucleotides in the target 39UTR are critical to miRNA suppression:
a sequence complementary to the 6-nucleotide seed sequence of the
miRNAs and 2 ﬂanking nucleotides (A1 and m8). Of the 146
patients carrying 1 or more nSNVs in the 39UTR, 95 (65%) had
Figure 2. Kaplan-Meier estimatesofOSandPFS inDLBCLpatientswithSNVs in theTP53 39UTR. (A)OSof patientswith orwithout SNPs. (B) PFSof patientswith orwithoutSNPs.
(C)OSof patientswith or without nSNVs. (D) PFSof patientswith or without nSNV. (E)OSof patientswith or without SNVs (either SNPor nSNV). (F) PFSof patientswith or without SNVs.
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nSNVs that disrupt and/or generate miRNA-binding sites as predicted
by TargetScan; 78 of 95 patients carried nSNVs disrupting putative
miRNA binding (Table 3; Figure 4B).
p53 expression analysis of 39UTR nSNVs
To test whether 39UTR variation impacts p53 expression, we intro-
duced gene expression cassettes carrying human TP53 complemen-
tary DNA (cDNA) with 39UTR variants in the miR-125b–binding
site (Figure 5A) into p53-null H1299 cells. As shown in Figure 5B,
TP53 39UTR nSNVs did not alter p53 expression compared with
WT. However, when cells were cotransfected with miR-125b, 3
nSNVs (733U, 737A, and 739A) disrupting the seed match between
miR-125b and the TP53 39UTR released the negative regulation of
p53 by miR-125b (Figure 5C). One variant (740A) that converts the
seed match from 7mer to 8mer, which is predicted to have a greater
effect on p53 downregulation, did not enhance p53 suppression by
miR-125b. These results demonstrate that miRNAs and nSNVs in
the TP53 39UTR signiﬁcantly alter p53 protein levels in vitro. We
next analyzed the relationship between p53 protein expression with
a 50% cutoff17 and 39UTR nSNVs in the initiation set. We found
that there was no correlation between nSNVs and p53 expression in
Figure 3. Kaplan-Meier estimates of OS and PFS in DLBCL patients classified according to TP53 CDS status. (A) OS of patients with or without an MUT-CDS. (B) PFS
of patients with or without an MUT-CDS. (C) OS of patients with a WT-CDS and nSNV. (D) PFS of patients with a WT-CDS and nSNVs. (E) OS of patients with an MUT-CDS
and nSNV. (F) PFS of patients with MUT-CDS and nSNVs.
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the entire cohort, the WT-CDS group, or the MUT-CDS group
(supplemental Table 5). There are at least 2 possibilities: (1) nSNVs
may have either inhibitory or stimulatory effects on p53 regulation;
and (2) the standard assay of p53 expression in tumors (percentage
of cells with positive staining rather the signal strength)17 cannot
detect the subtle modulation of p53 protein levels by nSNVs.
Functional significance of a germline polymorphism in the
TP53 39UTR
SNP rs78378222 (A1175C) is located in the polyadenylation signal
(PAS) of TP53 and is strongly associated with basal cell carcinoma
(BCC).30 This germline variant was found in 7 patients (6 A/C and
1 C/C). We predicted a decrease in p53 expression when the TP53
gene contains the PAS variant (AATAAA.AATACA). We intro-
duced gene expression cassettes carrying human TP53 cDNA with
this PAS variant (TP53ExtA1175C), or a control SNP rs114831472
(TP53ExtC1170T, not associated with BCC and other cancers)
located 1 nucleotide upstream of the PAS, and the 2.5-kb genomic
sequence downstream of the 39UTR (Figure 6A) into p53-null
H1299 cells. We found signiﬁcantly lower p53 protein levels in
cells with TP53ExtA1175C than in cells with WT control or
TP53ExtC1170T (Figure 6B). Northern blot analysis conﬁrmed that
p53 messenger RNA (mRNA) levels were downregulated in
cells with the p53 PAS variant (Figure 6C). We assessed the
effect of the TP53 PAS variant on apoptosis by using the ter-
minal deoxynucleotidyl transferase-mediated dUTP nick end la-
beling (TUNEL) assay. In cells harboring the p53 PAS minor
allele, cellular apoptosis was signiﬁcantly lower than that in cells
expressing the WT TP53 gene (Figure 6D). These data indicate
that the TP53 variant rs78378222 hinders p53 expression and its
downstream functions in apoptosis.
Discussion
In this work, we found many previously unreported SNVs in the
TP53 39UTR in DLBCL tumor DNA samples. 39UTR shortening31
Figure 4. Variation in the TP53 39UTR in 491 de novo DLBCL patients. (A) Distribution of SNVs in the 39UTR. (B) Potential effects of SNVs on the interaction of p53 mRNA
and miRNAs that are experimentally validated or predicted (by TargetScan) to target the TP53 39UTR. SNVs listed in dbSNP are marked with 3.
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Table 2. SNVs in the 39UTR disrupting the validated seed match of TP53:miRNA
TP53 39UTR and miRNA† Consequential pairing† Seed match‡
No. of patients*
Seed 1 m8 1 1A Other
Pos. 93-98 59 CUUUGAACCCUUGCU––UGCAAUA 7mer-1A 1(1) 0
|:: ||| ||||||
hsa-miR-25/92a 39 AGUCUGGCUCUGUUCACGUUAC
|x||||
nSNV 93G.A 59 CUUUGAACCCUUGCU––UACAAUA NO
Pos. 287-292 59 UGCAGUUAAGGGUUAGUUUACA 7mer-1A 1(1) 0
|||| |||||||
hsa-miR-30d 39 GAAGGUCAGCCCCUA––CAAAUGU
|||| x||||||
nSNV 287G.A 59 UGCAGUUAAGGGUUAAUUUACA NO
Pos.734-739 59 AAGACUUGUUUUAUGCUCAGGGU 7mer-m8 6(4) 3(2)
||| |||||||
hsa-miR-125b 39 AGUGUUCAAUCCCAGAGUCCCU
||| x|||x|xx
nSNV 733C.T 59 AAGACUUGUUUUAUGUUCAGGGU NO
nSNV 737G.C 59 AAGACUUGUUUUAUGCUCACGGU NO
nSNV 737G.A 59 AAGACUUGUUUUAUGCUCAAGGU NO
nSNV 739G.A 59 AAGACUUGUUUUAUGCUCAGGAU NO
nSNV 739G.C 59 AAGACUUGUUUUAUGCUCAGGCU NO
nSNV 740U.A 59 AAGACUUGUUUUAUGCUCAGGGA 8mer
Pos. 736-741 59 GACUUGUUUUAUGCUCAGGGUCA 8mer 6(5) 0
|||||||
hsa-miR-504 39 CUAUCUCACGUCUGGUCCCAGA
||x|xx|
nSNV 737G.C 59 GACUUGUUUUAUGCUCAAGGUCA NO
nSNV 737G.A 59 GACUUGUUUUAUGCUCACGGUCA NO
nSNV 739G.A 59 GACUUGUUUUAUGCUCAGGAUCA NO
nSNV 739G.C 59 GACUUGUUUUAUGCUCAGGCUCA NO
nSNV 740U.A 59 GACUUGUUUUAUGCUCAGGGCCA NO
Pos. 804-809 59 UGGGUCUCGCUUUGUUGCCCAGG 7mer-m8 3(2) 4(3)
:||||||:|||||||||||||
hsa-miR-1285 39 UCCAGAGUGAAACAACGGGUCU
:||||||:||||||||xx|||
nSNV 805C.T 59 UGGGUCUCGCUUUGUUGTCCAGG NO
nSNV 806C.T 59 UGGGUCUCGCUUUGUUGCTCAGG NO
Pos. 967-972 59 GGGGUCUCACAGUGUUGCCCAGG 7mer-m8 5(2) 2(2)
:|||||||| |||||||
hsa-miR-1285 39 UCCAGAGUGAAACAACGGGUCU
:|||||||| |||||||
nSNV 968C.T 59 GGGGUCUCACAGUGUUGTCCAGG NO
nSNV 969C.T 59 GGGGUCUCACAGUGUUGCTCAGG NO
Pos. 1065-1070 59 CCACGUCCAGCUGGAAGGGUCA 7mer-1A 4(3) 1(1)
||||||
hsa-miR-504 39 CUAUCUCACGUCUGGUCCCAGA
|x|x|x
nSNV 1066G.A 59 CCACGUCCAGCUGGAAAGGUCA NO
nSNV 1068G.A 59 CCACGUCCAGCUGGAAGGAUCA NO
SNP 1070C.T 59 CCACGUCCAGCUGGAAGGGUUA NO
nSNV 1071A.G 59 CCACGUCCAGCUGGAAGGGUCG 6mer
Pos. 1084-1089 59 GUCAACAUCUUUUACAUUCUGCAA ? 3(2) 6(5)
|| | | ||| | |||| |
hsa-miR-15 39 GUGUUUGGUAAUACACGACGAU
hsa-miR-16 39 GCGGUUAUAAAUGCACGACGAU
| || ||||| | |||| |
nSNV 1085C.T 59 GUCAACAUCUUUUACAUUCUGUAA
nSNV 1086A.G 59 GUCAACAUCUUUUACAUUCUGCGA
*Number of patients carrying SNVs affecting putative miRNA binding. Unique SNVs are indicated in parentheses. SNVs affecting TP53:miRNA complementarity other
than the seed match are not included. Underlining in the column 2 indicates the altered nucleotides.
†Nucleotides in the TP53 39 UTR are numbered starting from the one after the stop codon. Nucleotides complementary to the seed sequence (positions 2-7) of miRNAs
are indicated. Position (pos.) numbers correspond to nucleotides that are complementary to the miRNA seed sequence (in bold). rs114831472, affecting miR-504 binding, is
“SNP 1070C.T.” One miR-504 site overlaps with the miR-125b site. “x” indicates that base pairing is disrupted.
‡The 7mer-m8 site comprises the seed match supplemented by a Watson-Crick match to miRNA nucleotide 8. The 7mer-A1 site comprises the seed match
supplemented by an A across from miRNA nucleotide 1. The 8mer site comprises the seed match supplemented by both m8 and A1. “NO” indicates that the seed match was
abolished. “?” indicates unconventional interaction.
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and dysregulation of 39UTR-binding proteins32 or miRNAs33 in
cancer have been reported. This study, however, is the ﬁrst to
demonstrate that 39UTR variation is widespread in the TP53 gene in
cancer patients. Most DLBCLs originate from B cells in the germinal
center, which have a high proliferation rate and are prone to genomic
alterations.34 Germinal center B cells expand clonally and undergo
physiological somatic hypermutation of their immunoglobulin
variable-region genes and class-switch recombination to alter the
immunoglobulin subtype mediated by activation-induced cytidine
deaminase as part of the immune response. BCL2 point mutations in
DLBCL are suspected to be caused by this somatic hypermutation
mechanism.13 TP53 39UTR nSNVs found in this study are pre-
dominantly G→A and C→T substitutions, and the frequency ratio
of transition over transversion is 16.7, signiﬁcantly higher than 2.1
(for all human variants in dbSNP), 2.0 (TP53 CDS mutation in
DLBCL17), or 7.3 (known SNPs of TP53 39UTR). However, only
a small number of nSNVs are located in WRCY/RGYW sites
(IUPAC degenerated codes; supplemental Table 6), hot spots for
physiological hypermutations mediated by activation-induced cyti-
dine deaminase. In addition, these nSNVs are not found in many
projects that clearly sequence the full TP53 39UTR from hundreds of
individuals.35,36 Therefore, most nSNVs found in this study are likely
cancer-speciﬁc mutations rather than germline polymorphisms or
a result of a normally operative somatic hypermutation process. We
acknowledge that the absence of patient-matched noncancerous
tissue samples prevents us from completely ruling out the possibility
of rare private germline variants in these patients. Counting CDS
mutations and 39UTR nSNVs, ;45% of DLBCL patients (109 of
244) had alterations in TP53, making TP53 the most frequently
mutated gene identiﬁed in DLBCL. A recent study reported an R-
CHOP treatment-associated pattern of p53 and cell cycle dysregu-
lation in DLBCL,37 further emphasizing the importance of p53 in
DLBCL pathogenesis and prognosis.
Most of the TP53 39UTR nSNVs are located in validated or
putative miRNA-binding sites. Each speciﬁc mammalian cell
expresses;70 miRNAs at an appreciable level,38 yet normal B-cell
development and the initiation of malignancy and tumor pro-
gression are ordered and dynamic processes in which hundreds of
miRNAs are differentially expressed in more than a dozen
distinct cell populations.39-42 Thus, 39UTR variation may have
a direct biological impact on potential interactions between miRNAs
and p53 in B-cell maturation or DLBCL pathogenesis. Because
miRNAs repress gene expression, 39UTR alterations that are
predicted to disrupt miRNA-binding sites, as occurred in 78 of
146 patients with 1 or more nSNVs in this study (Table 3), could
reduce the efﬁciency of miRNA suppression and subsequently
increase p53 expression. This has been experimentally validated for
a few nSNVs located at the miR-125b site.We reasoned that when the
TP53 CDS is WT, the increased levels of tumor-suppressive p53
protein confer better 5-year survival in patients with 39UTR nSNVs,
as WT p53 is advantageous for patients undergoing R-CHOP
chemotherapy17; in contrast, when the TP53 CDS is mutated
concomitantly, the elevated levels of oncogenic p53 will worsen
survival in patients with 39UTR nSNVs. Our ﬁndings do show that
variation in the TP53 39UTR as a prognostic indicator of survival in
DLBCL patients is dependent on the status of the CDS, yet there is no
correlation between nSNV and p53 protein expression in the entire
cohort, the WT-CDS group, or the MUT-CDS group. It should be
noted that 39UTR variation may also disrupt interactions between
p53 mRNA and RNA-binding proteins, although the exact
nucleotides have not been pinpointed.43,44 Additionally, 39UTR
variation could affect mRNA stability or translation efﬁciency due
Table 3. Occurrence of nSNVs in the TP53 39UTR potentially
affecting miRNA binding in DLBCL
Subgroup
No. of patients (%)
Training Set
76 of 244
Validation Set
70 of 247
Total 146
of 491
TP53 CDS status
MUT-CDS 16 (21) NA NA
WT-CDS 60 (79) NA NA
39UTR nSNV affecting putative miRNA binding*
Generating only 12 5 17
Disrupting only 31 23 54
Generating and disrupting 15 9 24
Others 18 33 51
No. of 39UTR nucleotides altered
1 42 (59.5) 42 (60) 84 (57.5)
2 19 (23.8) 18 (25.7) 37 (25.3)
3 8 (9.5) 7 (10) 15 (10.3)
4 5 (4.8) 3 (4.3) 8 (5.5)
5 1 (1.2) 0 1 (0.7)
6 1 (1.2) 0 1 (0.7)
Others, outside seed match or not in miRNA sites; NA, not applicable.
*nSNVs predicted by TargetScan 5.0 to be targeted by miRNAs (based on the
seed sequence of the miRNA plus A1 and m8). Some patients had both mutations
generating miRNA binding and mutations disrupting it. Three SNPs listed in dbSNP
that putatively affect miRNA binding (rs16956880 [205 G.A], rs11483 1472 [1070
G.A], and rs78378222 [1175 C.A]) were excluded.
Figure 5. Expression analyses of TP53 39UTR variation affecting miR-125b
binding in p53-null cells. (A) Schematic representation of the p53 cDNA construct
and 39UTR variants. (B) Western blot of p53 expression in p53-null H1299 cells
transfected with p53 constructs. (C) Western blot of p53 expression in p53-null
H1299 cells transfected with p53 constructs with or without miR-125b. b-actin was
used as a control.
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to other mechanisms. Further investigation is needed to ascertain the
role of the nSNVs in p53 regulation and DLBCL prognosis.
The disappearance of the survival advantage at ;10 years for
DLBCL patients with a WT-CDS and nSNVs is noteworthy. The
frequency of TP53 CDS mutations may be higher in relapsed
DLBCL patients, and this may partially override the impact of 39UTR
variation on survival beyond 5 years. In patients with multiple
myeloma, the frequency of TP53 CDS mutations in de novo
disease is only ;3%, yet this number rises up to 30% in patients
with relapsed disease.45 Relapsed DLBCL is generally diagnosed
by imaging and limited sampling such as ﬁne-needle aspiration biopsy
rather than by excisional biopsy; the lack of adequate specimens for
genetic analysis precluded our testing for TP53 CDS mutations in
DLBCL patients at relapse and is a limitation of this study.
TP53 germline variants have been investigated for cancer sus-
ceptibility using genome-wide association studies, in which a type I
error rate (P-value threshold for signiﬁcance) of 1027 is generally
regarded as indicating genome-wide signiﬁcance.3,46 Until 2011, no
genome-wide association study reported a signiﬁcant association
between any germline TP53 polymorphism (other than Li-Fraumeni
Syndrome variants) and any cancer with a P value < 1027. In 2011,
however, rs78378222 was found to be strongly associated with BCC,
with an odds ratio (OR)5 2.16 (P5 2.23 10220).36 rs78378222 is
located in the ﬁfth nucleotide of the TP53 PAS that is required for
Figure 6. p53 expression and function for the TP53 PAS variant in p53-null cells. (A) Schematic representation of the TP53 constructs. Each carries a WT 59UTR, WT
CDS, a WT or mutant 39UTR, and a 2.5-kb native genomic sequence downstream of the TP53 PAS. (B) Western blot of p53 expression in p53-null H1299 cells transfected
with p53 constructs. b-actin was used as a control. OE, overexposure. (C) Northern blot of p53 mRNAs in H1299 cells carrying exogenous p53 genes. A housekeeping RNA
(H1RNA, the RNA subunit of human ribonuclease P) was used as a control. (D) Apoptosis of cells with p53 constructs; representative TUNEL images (left) and percentage of
TUNEL-positive cells (right). *P # .05.
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polyadenylation machinery recognition and subsequent cleavage,
polyadenylation, and export of mature mRNAs to the cytoplasm. The
risk-associated allele is a “C,” resulting in an alternative PAS
(AATACA) replacing the canonical PAS (AATAAA). Among
millions of SNPs in the human genome, rs78378222 has the strongest
association with BCC.36 This SNP is also associated with an
increased risk of prostate cancer (OR 5 1.44; P 5 2.4 3 1026),
glioma (OR 5 2.35; P 5 1.0 3 1025), and colorectal adenoma
(OR5 1.39; P5 1.63 1024),36 as well as esophageal squamous cell
carcinoma (OR 5 3.22; P 5 1.34 3 1024).47 In an independent
conﬁrmation study, rs78378222 was found to be associated with
a 3.5 times higher risk of glioma (P5 1.343 1024).48 Stefansson and
colleagues showed that rs78378222[A/C] heterozygotes expressed
“somewhat less” p53 transcript levels than WT homozygotes in
human blood specimens (P5 .041).36 In the present study, we tested
the role of the alternative PAS in p53 regulation using a p53-null cell
line with exogenous p53 constructs. We found that the C allele, as
compared with the A allele, dramatically lowers p53 mRNA levels
and results in reduced p53 protein expression and cellular apoptosis.
Our data are in agreement with a previous report that simian virus 40
mRNA with AATACA as PAS exhibits an eightfold decrease in
cleavage efﬁciency compared with the canonical site.49,50 These
ﬁndings provide direct evidence that rs78378222 negatively impacts
p53 expression and function. p53 stabilization and function rely on
various posttranslational modiﬁcations. As rs78378222 occurs in
the PAS signal of TP53, none of the downstream p53 protein
modiﬁcations are affected. Thus, this variant presents a unique
instance of TP53 alleles with unambiguous reduced function, in
contrast with most CDS mutants that are associated with a “loss of
function” and/or a “gain of function.”5
In summary, in this study we have shown that sequence variation
in the TP53 39UTR is frequent in DLBCL and that the role of this
sequence variation in patient survival depends on the status of the
TP53 CDS. To our knowledge, this study is the ﬁrst to demonstrate
the prognostic importance of the TP53 39UTR in cancer or any other
disease. The full extent of the pathobiology of 39UTR variants
remains to be determined.
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